CIC
RARE icon

Cornercap Investment Counsel’s Ultragenyx Pharmaceutical RARE Stock Holding History

Cornercap Investment Counsel’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,161
Closed -$241K – 676
2024
Q1 		$241K Buy
5,161
+15
+0.3% +$708 0.04% 544
2023
Q4 		$246K Buy
+5,146
New +$199K 0.04% 505

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Cornercap Investment Counsel's RARE Position: Q2 2024 in Review

Cornercap Investment Counsel sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2024, closing a stake of 5,161 shares — an estimated $241K sold.

Cornercap Investment Counsel first reported a position in RARE in Q4 2023 and held it in 2 quarters. The position peaked at $246K in Q4 2023. 274 funds tracked by Wall St. Rank hold RARE as of Q2 2024.

  • Cornercap Investment Counsel reported no remaining Ultragenyx Pharmaceutical position as of Q2 2024 after selling out during the quarter.
  • Cornercap Investment Counsel sold 5,161 Ultragenyx Pharmaceutical shares in Q2 2024, an estimated $241K.
  • Cornercap Investment Counsel first reported a position in Ultragenyx Pharmaceutical in Q4 2023 and held it in 2 quarters.
  • Cornercap Investment Counsel's Ultragenyx Pharmaceutical position peaked at $246K in Q4 2023.
  • 274 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2024.

Based on Cornercap Investment Counsel's 13F filing for Q2 2024, filed 8 Aug 2024.